Medicine Man Technologies Inc. Appoints Philippe Faraut as Interim CFO Amid Management Reshuffle

Reuters
Jul 19, 2025
<a href="https://laohu8.com/S/SHWZ">Medicine Man Technologies Inc.</a> Appoints Philippe Faraut as Interim CFO Amid Management Reshuffle

Medicine Man Technologies Inc. has appointed Philippe Faraut as the Interim Chief Financial Officer, effective July 14, 2025. Faraut brings over 25 years of experience in operational finance, capital markets, investment banking, and mergers and acquisitions. He previously served as CFO at iAnthus Capital Holdings, Inc. and has held key financial positions at companies like Irwin Naturals, Inc., Knight Global LLC, HSBC Securities USA Inc., and Merrill Lynch. Faraut holds degrees from the University of Southern California and UCLA Anderson School of Management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicine Man Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-069013), on July 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10